MBOT Microbot Medical Inc.
Price Chart
Executive Summary
Microbot Medical announced that it recorded revenue from its limited market release (LMR) of the LIBERTY Endovascular Robotic System in Q1 2026, and that Q2 2026 revenue mid-quarter has already exceeded total Q1 revenue. Accounts have more than doubled since the LMR ended, with hospitals in six states adopting the system. This indicates accelerating commercial adoption, though no specific revenue figures were disclosed.
Actionable Insight
Monitor upcoming 10-Q filing for actual Q1 and Q2 revenue figures and cash burn. Continued account growth and recurring orders support the commercial narrative, but valuation (market cap ~$146M) leaves no room for missteps in execution.
Key Facts
- Revenue recorded from LIBERTY System LMR during Q1 2026.
- Q2 2026 revenue (mid-quarter) has already exceeded total Q1 revenue.
- Number of accounts more than doubled since LMR ended.
- Hospitals in six states (GA, FL, NY, MI, MA, NC) have adopted the system.
- Boston became the first city/state with multiple accounts using LIBERTY.
Financial Impact
Undisclosed revenue amounts; Q2 2026 revenue mid-quarter exceeds Q1 total, but absolute figures not provided.
Risk Factors
- No specific revenue or profitability data disclosed; early-stage adoption risks.
- Small company with limited revenue; cash burn and potential dilution remain concerns.
- Historical stock performance on prior news has been negative (avg T+20 -7.3%).
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022886 |
| Exhibit: ex99-1.htm | 0001493152-26-022886 |
| Document: 0001493152-26-022886-index-headers.html | 0001493152-26-022886 |
| Document: 0001493152-26-022886-index.html | 0001493152-26-022886 |
| Document: 0001493152-26-022886.txt | 0001493152-26-022886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
8d ago
|
8-K
| $1.91 awaiting T+5 | awaiting T+5 | — | $1.71 (−10.47%) |
|
May 14, 2026
9d ago
|
8-K
| $2.16 awaiting T+5 | awaiting T+5 | — | $1.71 (−20.83%) |
|
May 5, 2026
18d ago
|
8-K
| $2.10 $2.19 | ▲ +4.29% | ▲ +2.30% | $1.71 (−18.57%) |
|
Apr 22, 2026
4w ago
|
8-K
| $2.22 $2.09 | ▼ −6.08% | ▼ −6.14% | $1.71 (−22.97%) |
|
Apr 14, 2026
5w ago
|
8-K
| $2.43 $2.15 | ▼ −11.52% | ▼ −12.92% | $1.71 (−29.63%) |
|
Apr 13, 2026
5w ago
|
8-K
| $2.35 $2.30 | ▼ −2.13% | ▼ −5.42% | $1.71 (−27.23%) |
|
Mar 24, 2026
8w ago
|
Press Release
| $2.50 $2.41 | ▼ −3.60% | ▼ −3.18% | $1.71 (−31.60%) |
|
Feb 24, 2026
12w ago
|
8-K
| $2.59 $2.45 | ▼ −5.41% | ▼ −4.31% | $1.71 (−33.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access